refractory cancer
Showing 1 - 25 of 43
Head Neck Cancer, Relapse, Recurrent Trial in Chapel Hill (Cyclophosphamide, Fludarabine, Cell Therapy)
Not yet recruiting
- Head and Neck Cancer
- +3 more
- Cyclophosphamide
- +2 more
-
Chapel Hill, North CarolinaLineberger Comprehensive Cancer Center at University of North Ca
Oct 18, 2023
Refractory Cancer, Relapsed Cancer Trial in Weston (Drug Sensitivity Test (DST))
Not yet recruiting
- Refractory Cancer
- Relapsed Cancer
- Drug Sensitivity Test (DST)
-
Weston, FloridaLerner College of Medicine: Cleveland Clinic Florida
Sep 1, 2023
Pathologically Confirmed Cancer Refractory to Conventional Therapy, Refractory Cancer, Metastatic Cancer Trial in Santa Monica
Not yet recruiting
- Pathologically Confirmed Cancer Refractory to Conventional Therapy
- +7 more
- SNK02
-
Santa Monica, CaliforniaSarcoma Oncology Center
Aug 10, 2023
Refractory Cancer, Recurrent Cancer, Solid Tumor, Adult Trial in Germany (IMA402 (Phase Ia), IMA402 (Phase Ib), IMA402 (Phase
Not yet recruiting
- Refractory Cancer
- +3 more
- IMA402 (Phase Ia)
- +2 more
-
Heidelberg, Baden-Wuerttemberg, Germany
- +12 more
Jul 14, 2023
Solid Tumor, Adult, Advanced Solid Tumor, Head Neck Cancer Trial in Irving, San Antonio, West Valley City (SNS-101 (anti-VISTA),
Recruiting
- Solid Tumor, Adult
- +19 more
- SNS-101 (anti-VISTA)
- Cemiplimab
-
Irving, Texas
- +2 more
May 24, 2023
Cutaneous Squamous Cell Carcinoma, SCC - Squamous Cell Carcinoma, Basal Cell Carcinoma Trial in United States (MQ719,
Recruiting
- Cutaneous Squamous Cell Carcinoma
- +18 more
- MQ719
- Pembrolizumab
-
Basking Ridge, New Jersey
- +6 more
May 18, 2023
Solid Tumor, Adult, Metastatic Solid Tumor, Refractory Cancer Trial (ADU-1805, Pembrolizumab)
Not yet recruiting
- Solid Tumor, Adult
- +2 more
- (no location specified)
May 3, 2023
Large Cell Lymphoma, Diffuse, Relapsed Cancer, Refractory Cancer Trial (AutoSCT, GDP, Epcoritamab)
Not yet recruiting
- Large Cell Lymphoma, Diffuse
- +2 more
- AutoSCT
- +2 more
- (no location specified)
May 10, 2023
Acute Myeloid Leukemia, Relapsed Cancer, Refractory Cancer Trial in Edmonton, Toronto (Enasidenib, Venetoclax)
Active, not recruiting
- Acute Myeloid Leukemia
- +3 more
-
Edmonton, Alberta, Canada
- +1 more
Jan 31, 2023
Precision Medicine for Every Child With Cancer
Recruiting
- Childhood Cancer
- +5 more
- Whole Genome Sequencing
- +6 more
-
Adelaide, Australia
- +8 more
Jan 24, 2023
Colorectal Cancer, Colorectal Carcinoma, Colorectal Adenocarcinoma Trial run by the NCI (Durvalumab, Tremelimumab, Pexa-Vec)
Active, not recruiting
- Colorectal Cancer
- +4 more
- Durvalumab
- +2 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Jan 24, 2023
Relapsed Solid Tumor, Refractory Cancer, Solid Tumor, Adult Trial (STI-3258)
Withdrawn
- Relapsed Solid Neoplasm
- +2 more
- STI-3258
- (no location specified)
Jan 24, 2023
Usability of Cellworks Singula™ and Cellworks Ventura™ Reports
Recruiting
- Cancer
- +2 more
- Cellworks Report
-
Sioux Falls, South DakotaAvera Cancer Institute
Jan 20, 2023
Primary CNS Lymphoma, Secondary CNS Lymphoma, Relapsed Cancer Trial in Miami (drug, procedure, radiation)
Not yet recruiting
- Primary Central Nervous System Lymphoma
- +3 more
- Pemetrexed
- +3 more
-
Miami, FloridaMiami Cancer Institute at Baptist Health, Inc.
Dec 23, 2022
Prostate Cancer, Refractory Cancer, Castration Resistant Prostatic Cancer Trial in Winston-Salem (Omeprazole 80 mg twice daily)
Recruiting
- Prostate Cancer
- +2 more
- Omeprazole 80 mg twice daily
-
Winston-Salem, North CarolinaWake Forest Baptist Comprehensive Cancer Center
Jan 5, 2023
Solid Tumor, Adult, Refractory Cancer Trial (GV20-0251)
Not yet recruiting
- Solid Tumor, Adult
- Refractory Cancer
- (no location specified)
Dec 21, 2022
Solid Tumor, Adult, Relapsed Cancer, Refractory Cancer Trial (HST-1011, Cemiplimab)
Not yet recruiting
- Solid Tumor, Adult
- +2 more
- HST-1011
- Cemiplimab
- (no location specified)
Dec 14, 2022
Refractory Cancer, Recurrent Cancer, Solid Tumor, Adult Trial in Germany (IMA401 (Phase Ia), IMA401 (Phase Ib))
Recruiting
- Refractory Cancer
- +3 more
- IMA401 (Phase Ia)
- IMA401 (Phase Ib)
-
Tübingen, Baden-Wurttemberg, Germany
- +16 more
Dec 19, 2022
Refractory Cancer, Metastatic Cancer, Recurrent Cancer Trial in Santa Monica (SNK01, Avelumab, Pembrolizumab)
Active, not recruiting
- Refractory Cancer
- +6 more
- SNK01
- +2 more
-
Santa Monica, CaliforniaSarcoma Oncology Research Center
Sep 25, 2022
Advanced Solid Tumor, Metastatic Cancer, Refractory Cancer Trial in Huntersville, Houston, Webster (PT199, Anti-PD-1 mAb)
Recruiting
- Advanced Solid Tumor
- +18 more
- PT199
- Anti-PD-1 monoclonal antibody
-
Huntersville, North Carolina
- +2 more
Aug 10, 2022
Refractory Cancer Trial in Hamburg (BIBW 2992 (Afatinib))
Terminated
- Refractory Cancer
- BIBW 2992 (Afatinib)
-
Hamburg, GermanyUniversity Medical Center Hamburg-Eppendorf
Jun 29, 2022
Refractory Cancer Trial in Seoul (AZD6738, Paclitaxel)
Completed
- Refractory Cancer
-
Seoul, Korea, Korea, Republic ofSamsung Medical Center
Jun 13, 2022